Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndromeKelly S. Chien, Guillermo Garcia‐Manero, Kunhwa Kim et al.|British Journal of Haematology|2021Cited by 64
Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activationYasmin Abaza, Guillermo Garcia‐Manero, Farhad Ravandi et al.|Leukemia Research|2018Cited by 9